Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin glargine + lixisenatide fixed-ratio combination versus GLP-1 receptor agonist in adults with inadequately controlled type 2 diabetes
2014-004850-32Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in HbA1c. Started May 2016; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-004850-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004850-32.